Survival Rates for Castleman Disease

Doctors often use survival rates as a standard way of discussing a person’s outlook (prognosis). Survival rates tell you what portion of people with the same type and stage of disease are still alive a certain amount of time after they were diagnosed. They can’t tell you how long you will live, but they may help give you a better understanding about how likely it is that your treatment will be successful.

It’s hard to get accurate numbers on the outlook for people with CD because it is rare. Most statistics on the disease come from small numbers of patients who were treated at a single center or hospital. These numbers might not accurately reflect the outcomes for all people with CD.

The numbers below come from a study of nearly 200 people treated for CD in many different centers. The study divided people into groups based on whether the CD was unicentric or multicentric, its microscopic subtype, and whether the patient was infected with HIV (HIV+) or not infected (HIV-).

The 3-year disease-free survival (DFS) rate refers to the percentage of patients who were still alive and had no signs of CD at least 3 years after it was diagnosed. Of course, many people went much longer than 3 years without any signs of CD (and many were likely cured).

Type of Castleman Disease

3-Year Disease-Free Survival

Unicentric, hyaline vascular, HIV-


Unicentric, plasma cell or mixed, HIV-, OR
Multicentric, hyaline vascular, HIV-


Multicentric, plasma cell, HIV-


HIV+ (multicentric)


Even when taking the factors above into account, disease-free survival rates are at best rough estimates. If you have CD, your doctor can tell you how well these numbers might apply to you, as he or she knows your situation best.

The American Cancer Society medical and editorial content team

Our team is made up of doctors and oncology certified nurses with deep knowledge of cancer care as well as journalists, editors, and translators with extensive experience in medical writing.

Castleman Disease Collaborative Network. About Castleman disease. Accessed January
5, 2018.   

Liu AY, Nabel CS, Finkelman BS, Ruth JR, Kurzrock R, van Rhee F, et al. Idiopathic multicentric Castleman’s disease: A systematic literature review. Lancet Haematol 2016;3(4):e163-165.

National Organization for Rare Disorders. Castleman disease. Accessed at on January 5, 2018. 

Oksenhendler E, Boutboul D, Fajgenbaum D, Mirouse A, Fieschi C, Malphettes M, Vercellino L, Meignin V, Gerard L, Galicier L. The full spectrum of Castleman disease: 273 patients studied over 20 years. Hematol Oncol Clin North Am. 2018;32(1):75-88.

Talat N, Schulte KM. Castleman’s disease: Systematic analysis of 416 patients from the literature. Oncologist. 2011;16:1316–1324. 

Zhang X, Rao H, Xu X, Li Z, Liao B, Wu H, Li M, Tong X, Li J, Cai Q. Clinical characteristics and outcomes of Castleman disease: A multicenter study of 185 Chinese patients. Cancer Sci. 2017 Nov [Epub ahead of print]. 

Last Revised: February 8, 2018

American Cancer Society medical information is copyrighted material. For reprint requests, please see our Content Usage Policy.